Hepatic artery injection of super(131)I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study

Hepatic artery injection of super(131)I-labelled metuximab combined with chemoembolization for intermediate hepatocellular carcinoma: a prospective nonrandomized study

Purpose: Hepatocellular carcinoma (HCC) is the fifth and seventh most common cause of cancer in men and women, respectively. Transcatheter arterial chemoembolization (TACE) is the standardized therapy for the intermediate stage of HCC. However, the 3-year overall survival remains low (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of nuclear medicine and molecular imaging 2012-08, Vol.39 (8), p.1306-1315
Hauptverfasser: Wu, Lu, Yang, Ye-Fa, Ge, Nai-Jian, Shen, Shu-Qun, Liang, Jun, Wang, Yi, Zhou, Wei-Ping, Shen, Feng, Wu, Meng-Chao
Format: Artikel
Sprache:eng
Schlagworte:
Age
Albumin
hepatic artery
Hepatocellular carcinoma
Multivariate analysis
Nuclear medicine
Survival
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Purpose: Hepatocellular carcinoma (HCC) is the fifth and seventh most common cause of cancer in men and women, respectively. Transcatheter arterial chemoembolization (TACE) is the standardized therapy for the intermediate stage of HCC. However, the 3-year overall survival remains low (
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-012-2145-5